These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 31692240)
1. Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules. Kim JH; Ko HY; Wang HJ; Lee H; Yun M; Kang ES Diabetes Obes Metab; 2020 Mar; 22(3):373-382. PubMed ID: 31692240 [TBL] [Abstract][Full Text] [Related]
2. Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis Sun X; Cao Z; Ma Y; Shao Y; Zhang J; Yuan G; Guo X Food Funct; 2021 Feb; 12(3):1207-1218. PubMed ID: 33432947 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway. Lee J; Hong SW; Kim MJ; Lim YM; Moon SJ; Kwon H; Park SE; Rhee EJ; Lee WY Endocrinol Metab (Seoul); 2024 Feb; 39(1):98-108. PubMed ID: 38171209 [TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109 [TBL] [Abstract][Full Text] [Related]
12. Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. Sasaki M; Sasako T; Kubota N; Sakurai Y; Takamoto I; Kubota T; Inagi R; Seki G; Goto M; Ueki K; Nangaku M; Jomori T; Kadowaki T Diabetes; 2017 Sep; 66(9):2339-2350. PubMed ID: 28630133 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma. Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435 [TBL] [Abstract][Full Text] [Related]
15. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006 [TBL] [Abstract][Full Text] [Related]
16. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371 [TBL] [Abstract][Full Text] [Related]
17. FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake. Li L; Zhao H; Chen B; Fan Z; Li N; Yue J; Ye Q J Transl Med; 2019 Dec; 17(1):418. PubMed ID: 31836014 [TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Neumiller JJ; White JR; Campbell RK Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482 [TBL] [Abstract][Full Text] [Related]
19. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Gerich JE; Bastien A Expert Rev Clin Pharmacol; 2011 Nov; 4(6):669-83. PubMed ID: 22111852 [TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]